2462 PUBLICATIONS
ANNÉE
JOURNAL
PREMIER AUTEUR
TITRE
ANNÉE2024
JOURNALHeliyon
PREMIER AUTEURLerouge L
TITRENon-targeted effects of radiation therapy for glioblastoma.
ANNÉE2024
JOURNALEuropean journal of nuclear medicine and molecular imaging
PREMIER AUTEURTreglia G
TITRE[F]Fluorocholine PET/CT as First-Line vs. Second-Line Imaging Method to localize parathyroid adenomas in primary hyperparathyroidism: "Game, Set, and Match".
ANNÉE2024
JOURNALCancers
PREMIER AUTEURAndré C
TITREHER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity.
ANNÉE2024
JOURNALSurgery
PREMIER AUTEURAddeo P
TITREMinimally invasive versus open distal pancreatectomy for resectable pancreatic neuroendocrine tumors: A propensity score matched multicentric comparative French study.
ANNÉE2024
JOURNALCancers
PREMIER AUTEURLebas A
TITREComplications and Risk Factors in Patients with Soft Tissue Sarcoma of the Extremities Treated with Radiotherapy.
ANNÉE2024
JOURNALJournal of experimental & clinical cancer research : CR
PREMIER AUTEURDurand M
TITREA first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
ANNÉE2024
JOURNALCancers
PREMIER AUTEURHerbein G
TITRECellular Transformation by Human Cytomegalovirus.
ANNÉE2024
JOURNALBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
PREMIER AUTEURSomme LB
TITREAntibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers.
ANNÉE2024
JOURNALRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
PREMIER AUTEURBorel C
TITREStandard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
ANNÉE2024
JOURNALDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
PREMIER AUTEURBotsen D
TITRETrifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

Retrouvez aussi

Personnes
Equipes
Plateformes
Unités de recherche, établissements
Projets de recherche
Publications scientifiques